Selank

Selank is a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an anxiolytic nootropic with GABAergic and monoaminergic activity.

Selank is a synthetic heptapeptide analogue of tuftsin (threonyl-lysyl-prolyl-arginine), an endogenous immunomodulatory peptide. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank has been extensively studied for its anxiolytic, nootropic, and immunomodulatory properties, and is approved in Russia as a nasal spray for the treatment of anxiety and neurasthenia.

Overview

Selank was designed by extending the natural tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tripeptide tail to improve metabolic stability. This modification preserves tuftsin's immunomodulatory activity while conferring potent anxiolytic and nootropic effects mediated through GABAergic and monoaminergic systems. Unlike benzodiazepines, Selank produces anxiolysis without sedation, cognitive impairment, or dependence liability. Its dual action on both the immune and nervous systems makes it a unique peptide in the regulatory peptide class.

Mechanism of Action

Selank exerts its anxiolytic effects primarily through modulation of the GABAergic system, enhancing inhibitory neurotransmission without directly binding to benzodiazepine receptors. It influences the metabolism and release of monoamine neurotransmitters, including serotonin, dopamine, and norepinephrine, contributing to its anxiolytic and mood-stabilizing properties.

The peptide also increases brain-derived neurotrophic factor (BDNF) expression, supporting neuronal plasticity, survival, and differentiation. Its immunomodulatory activity derives from its tuftsin core, which activates phagocytic cells and modulates cytokine production. Selank has been shown to influence the expression of genes encoding enkephalins and inflammatory cytokines, linking its neuromodulatory and immunoregulatory actions.

Reconstitution Calculator

Selank

Selank is a synthetic heptapeptide analogue of tuftsin (threonyl-lysyl-prolyl-ar

Draw Volume
0.100mL
Syringe Units
10units
Concentration
2,500mcg/mL
Doses / Vial
20doses
Vial Total
5mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
Recommended Schedule
M
T
W
T
F
S
S
FrequencyDaily
TimingMorning
Cycle2-4 weeks
NoteIntranasal also effective; dose range 250-500mcg
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 5mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

7x / week for weeks

·
40%
2vials
28 doses20 days/vial12 leftover
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Blood-Brain Barrier Penetration

As a glyproline peptide, Selank exhibits inherent BBB permeability superior to most oligopeptides. Glyprolines are well known for regulatory, protective, and repair-promoting effects throughout the body (Bakaeva et al., 2017). The N-acetylation and amidation of Selank further enhance this BBB penetration, increasing both the amount of peptide reaching the CNS and its receptor binding potency once there.

Anxiety

Perhaps the most thoroughly studied property of Selank is its anxiolytic activity. Research shows effects comparable to benzodiazepines, including reduced anxiety, lower stress, and improved mood via interaction with the GABAA receptor system (Volkova et al., 2016). Critically, Selank does not appear to be habit-forming, unlike benzodiazepines which carry well-known abuse and dependence potential. Selank may even assist in weaning patients from benzodiazepine dependence.

Combination studies with benzodiazepines have shown additive benefits, particularly in treating the often-resistant form of anxiety known as unpredictable chronic mild stress (Kasian et al., 2016).

Modifications: Acetylation and Amidation

N-Acetylation alters the charge, hydrophobicity, and size of the peptide, primarily extending half-life without affecting overall function (Linster & Wirtz, 2018; Ree et al., 2018). Most human proteins are naturally N-acetylated, making this a well-characterized modification.

Amidation protects against proteolytic degradation, enhances pH stability, increases receptor binding affinity, and improves lipid solubility for better BBB penetration. Natural amidated peptides include oxytocin, thyroid releasing hormone, and vasopressin. The combination of both modifications produces synergistic enhancement of Selank's CNS activity.

Anticoagulant Properties

Animal studies have revealed that Selank helps regulate the coagulation cascade, maintaining homeostasis and offsetting effects of both hypercoagulation and, to a lesser extent, bleeding (Liapina et al., 2006). Supporting this, research in rat mesenteric vessels shows that glyprolines prevent microcirculation hypercoagulation resulting from immobilization (Kopylova et al., 2003). This gentle regulation of coagulation without overcompensation makes Selank attractive for developing blood clot prophylactics as an alternative to heparin.

Gene Expression Effects

Selank influences the expression of genes encoding enkephalins and inflammatory cytokines, providing a molecular basis for its combined anxiolytic and immunomodulatory actions. These gene-level effects connect neuroendocrine and immune system regulation through shared peptidergic pathways.

Ongoing & Future Research

  • Investigation of N-Acetyl Selank Amidate as an enhanced-stability derivative with potentially superior pharmacokinetics
  • Research into Selank's effects on microglial activation and neuroinflammation in neurodegenerative disease models
  • Exploration of Selank in PTSD and trauma-related anxiety, building on its GABAergic and enkephalinergic mechanisms
  • Studies on Selank's gut-brain axis effects given its tuftsin-derived immunomodulatory properties and the gut immune system's role in anxiety
  • Interest in Selank for withdrawal symptom management (alcohol, benzodiazepine) given its GABAergic effects without dependence liability

Nootropic and Cognitive Enhancement

Research has demonstrated nootropic activity of Selank in animal models, with improvements in learning and memory consolidation. These effects are associated with modulation of neurotransmitter systems and enhanced neurotrophic factor expression in brain regions critical for cognition. Kozlovskii & Danchev (2003) — Neurosci. Behav. Physiol.

Immune Modulation

As a tuftsin analogue, Selank retains immunomodulatory properties including enhancement of phagocyte activity and regulation of cytokine balance. Studies have demonstrated its capacity to modulate both innate and adaptive immune responses, suggesting potential applications in immune dysregulation. Uchakina et al. (2008) — Int. Immunopharmacol.

Neuroprotection and BDNF

Selank increases expression of BDNF and modulates monoamine neurotransmitter levels in the brain, supporting neuronal survival, plasticity, and differentiation. Its interaction with the GABA system has been confirmed through studies showing altered GABAergic signaling following Selank administration. Kozlovskaya et al. (2003) — Bull. Exp. Biol. Med.

Cognitive Enhancement

Nasal administration of Selank in rats produces changes in mRNA levels for 36 different genes associated with plasma membrane function and ion-dependent learning and memory (Kolomin et al., 2013). Treated rats show increased memory trace stability, resulting in greater long-term retention of learning. Selank also rescues memory and learning following brain damage by inhibiting the catecholamine system and offsetting excitotoxic neuron death -- a process seen in head injury, drug overdose, and neurodegenerative diseases like Parkinson's disease.

Selank increases BDNF levels, which stimulates neuronal growth and differentiation. The enhanced BBB penetration of N-Acetyl Selank Amidate likely makes it a more potent nootropic than standard Selank.

Immune System

Animal studies demonstrate that Selank suppresses production of the inflammatory cytokine IL-6 (Uchakina et al., 2008). IL-6 is secreted by macrophages, bone marrow cells, and blood vessel cells. It mediates fever, neutrophil production, B cell growth, and in the CNS plays roles in sleep-associated memory consolidation and pain perception.

Research in rats suggests that Selank may modulate IL-6 expression in the CNS and thereby help reduce pain associated with asthenic symptoms in psychiatric conditions (Zozulia et al., 2008). This observation supports the hypothesis of a link between psychiatric conditions and physical pain, and suggests glyprolines may serve as regulators of neurogenic pain.

Anxiolytic Effects

Selank produces anxiolytic effects comparable to benzodiazepines in animal models of anxiety, without the associated sedation, muscle relaxation, or dependence. Its mechanism involves modulation of GABAergic neurotransmission and monoamine metabolism, providing a distinct pharmacological profile from classical anxiolytics. Zozulya et al. (2001) — Bull. Exp. Biol. Med.

Comparative studies have confirmed Selank's anxiolytic potency across multiple behavioral paradigms, demonstrating efficacy in both acute and chronic anxiety models. Seredenin et al. (2008) — Bull. Exp. Biol. Med.

Neurological/Immunological Mechanisms

GABAergic modulation:

  • Selank enhances GABAergic inhibitory neurotransmission without direct benzodiazepine receptor binding (Kozlovskaya et al., PMID: 14631520)
  • Modulates GABA-A receptor sensitivity through allosteric mechanisms
  • Unlike benzodiazepines, does not downregulate GABA receptor expression with chronic use, explaining the absence of tolerance and dependence

Monoamine modulation:

  • Increases serotonin metabolism and turnover in the hippocampus, frontal cortex, and hypothalamus
  • Modulates dopamine and norepinephrine levels in emotion-regulating brain regions
  • Stabilizes the serotonin/norepinephrine balance, contributing to mood-stabilizing effects distinct from SSRIs

Neurotrophic signaling:

  • Upregulates BDNF expression, activating TrkB → PI3K/Akt and MAPK/ERK pathways
  • Promotes neuronal plasticity, dendritic branching, and synaptogenesis in hippocampal circuits
  • BDNF effects contribute to both anxiolytic and nootropic properties

Immunological mechanisms (tuftsin core):

  • The Thr-Lys-Pro-Arg tetrapeptide core activates phagocytic cells via tuftsin receptors (neuropilin-1/NRP1)
  • Enhances macrophage phagocytosis, neutrophil chemotaxis, and natural killer cell activity
  • Modulates cytokine production: influences IL-6, TNF-α, and enkephalin gene expression
  • Regulates the balance between pro-inflammatory and anti-inflammatory cytokine networks

Enkephalin gene regulation:

  • Selank influences proenkephalin gene expression, connecting its anxiolytic effects to endogenous opioid peptide systems
  • This enkephalin modulation may partially explain its analgesic and stress-protective properties

Safety Profile

Selank is approved in Russia as a nasal spray (0.15% solution) for the treatment of anxiety disorders and neurasthenia. Clinical studies and post-marketing surveillance have demonstrated a favorable safety profile with minimal reported adverse effects. No sedation, cognitive impairment, dependence, or withdrawal symptoms have been observed, distinguishing Selank from benzodiazepine anxiolytics. No significant adverse events have been reported in clinical trials. Its short half-life limits systemic accumulation risk. Long-term safety data outside of Russian clinical settings remain limited.

Pharmacokinetic Profile

Selank — Pharmacokinetic Curve

Intranasal
0%25%50%75%100%0m6m12m18m24m30mTimeConcentration (% peak)T_max 8mT_1/2 6m
Half-life: 6mT_max: 20mDuration shown: 30m

Quick Start

Typical Dose
250-500mcg per dose
Frequency
1-2x daily (morning and/or evening)
Route
Intranasal
Cycle Length
2-8 weeks on
Storage
Reconstituted: 2-8°C, use within 30 days

Molecular Structure

2D Structure
Selank molecular structure
Molecular Properties
Formula
C33H57N11O9
Weight
751.89 Da
Length
7 amino acids
CAS
129954-34-3
PubChem CID
11765600
Exact Mass
751.4341 Da
LogP
-6.1
TPSA
322 Ų
H-Bond Donors
9
H-Bond Acceptors
12
Rotatable Bonds
19
Complexity
1360
Identifiers (SMILES, InChI)
InChI
InChI=1S/C33H57N11O9/c1-19(45)26(35)29(49)41-20(8-2-3-13-34)30(50)44-17-6-11-23(44)28(48)40-21(9-4-14-38-33(36)37)31(51)43-16-5-10-22(43)27(47)39-18-25(46)42-15-7-12-24(42)32(52)53/h19-24,26,45H,2-18,34-35H2,1H3,(H,39,47)(H,40,48)(H,41,49)(H,52,53)(H4,36,37,38)/t19-,20+,21+,22+,23+,24+,26+/m1/s1
InChIKeyJTDTXGMXNXBGBZ-YVHUGQOKSA-N

Research Indications

Anxiety

Strong Evidence
Generalized Anxiety Disorder

Clinical trials show significant reduction in anxiety symptoms comparable to benzodiazepines but without sedation or amnesia.

Good Evidence
Post-Traumatic Stress Disorder

Research indicates effectiveness in PTSD treatment.

Good Evidence
Social Anxiety

Reduces anticipatory anxiety and performance stress.

Cognitive

Good Evidence
Memory Enhancement

Improves memory consolidation and learning capacity.

Good Evidence
Attention and Focus

Enhanced sustained attention during demanding cognitive tasks.

Good Evidence
Neuroprotection

BDNF upregulation supports long-term brain health.

Immune

Moderate Evidence
Immune Modulation

Balances immune system function through cytokine regulation.

Moderate Evidence
Antiviral Activity

Shows activity against influenza, HSV, and cytomegalovirus.

Moderate Evidence
Inflammation Regulation

Modulates inflammatory gene expression.

Neurological

Good Evidence
Generalized anxiety disorder

Enhanced stability analog of Selank (tuftsin derivative). Selank is approved in Russia for anxiety disorders. The N-acetyl amidate form has improved bioavailability and BBB penetration. Anxiolytic effects are mediated through GABA-ergic modulation without sedation.

Moderate Evidence
Cognitive enhancement

Modulates BDNF and NGF expression, enhancing memory consolidation and learning. Animal studies show improved performance in memory tasks. The acetylated form provides prolonged nootropic activity compared to native Selank.

Moderate Evidence
Stress resilience

Normalizes stress-induced changes in brain monoamine levels (serotonin, dopamine, norepinephrine) in animal models. Stabilizes enkephalin degradation, prolonging endogenous anxiolytic peptide activity.

Immunological

Moderate Evidence
Immune modulation

As a tuftsin analog, N-Acetyl Selank Amidate retains immunomodulatory properties. Influences IL-6, T-helper cell balance, and innate immune function. Selank has demonstrated antiviral properties against influenza in preclinical studies.

Research Protocols

subcutaneous Injection

Anxiolytic neuropeptide administered subcutaneously. Cycle pattern: 4 weeks on, 4 weeks off to prevent tachyphylaxis.

GoalDoseFrequency
Loading phase300 mcgOnce daily
Full dose500 mcgOnce daily
Reconstitution Guide (5mg vial + 3mL BAC water)
  1. Wipe vial tops with alcohol swab
  2. Draw 3.0 mL bacteriostatic water into syringe
  3. Inject slowly down the inside wall of the peptide vial
  4. Gently swirl to dissolve — never shake
  5. Resulting concentration: 1.67 mg/mL
  6. For 300 mcg dose: draw 18 units (0.18 mL)
  7. For 500 mcg dose: draw 30 units (0.30 mL)
  8. Store reconstituted vial refrigerated at 2-8°C

intranasal Injection

Intranasal spray provides fastest onset (15-30 minutes) and is non-invasive. Popular for as-needed anxiety relief.

GoalDoseFrequency
Acute anxiety relief300-600mcg (1-2 sprays)Once daily or as-needed

Interactions

Peptide Interactions

Semaxsynergistic

Enhanced cognitive and anxiolytic effects when combined.

BPC-157compatible

Complementary stress response mechanisms.

Noopeptcompatible

Both enhance BDNF via different pathways.

Phenylpiracetamcompatible

Balanced anxiety relief and cognition enhancement.

Modafinilcompatible

Balanced anxiety reduction and wakefulness.

Benzodiazepinescaution

Selank exhibits anxiolytic effects similar to low-dose benzodiazepines (diazepam, phenazepam) via allosteric modulation of the GABAA receptor, but without amnesia, withdrawal, or dependence. Co-administration with benzodiazepines may produce additive CNS depressant effects. Source: Kasian et al., Front Pharmacol 2016 (PMC4757669).

What to Expect

What to Expect

30-60 minutes

Mild anxiety reduction begins

1-3 days

Improved mental clarity and focus

1 week

Enhanced stress resilience and emotional stability

1-2 weeks

Peak cognitive enhancement effects

Post-discontinuation

Sustained benefits for several days

Safety Profile

Common Side Effects

  • Minimal side effects - excellent safety profile
  • No sedation or cognitive impairment
  • No tolerance, dependence, or withdrawal

Contraindications

  • Known peptide allergies
  • Pregnancy or breastfeeding
  • Consult healthcare provider with multiple psychiatric medications

Discontinue If

  • Severe allergic reactions (rash, breathing difficulty, swelling)
  • Persistent injection site reactions or infection signs
  • Unusual mood changes or increased anxiety
  • Severe headaches or neurological symptoms
  • Contaminated product signs (unusual smell, cloudiness)
  • Unexplained fatigue or cognitive impairment
  • Skin reactions or immune hypersensitivity

Quality Indicators

What to look for

  • White to off-white lyophilized powder without clumping
  • Clear, colorless reconstituted solution
  • Clear batch information, purity testing, expiration dates
  • Appropriate packaging and cold shipping

Caution

  • Unusual smell or burning sensation may indicate bacterial contamination
  • Room temperature shipping of nasal spray

Red flags

  • Yellowing, clumping, or moisture exposure
  • Persistent cloudiness after reconstitution

Frequently Asked Questions

References (14)

  1. [9]
    Seredenin, S. B. et al Comparative analysis of anxiolytic effect of Selank Bull. Exp. Biol. Med. (2008)
  2. [10]
    Kozlovskii, I. I. & Danchev, N. D Nootropic activity of Selank Neurosci. Behav. Physiol. (2003)
  3. [1]
    GABAergic Gene Expression Study (2016)
  4. [2]
    GAD Clinical Trial (2008)
  5. [3]
    BDNF Enhancement Study (2010)
  6. [4]
    Memory Consolidation Study (2007)
  7. [5]
    Inflammation-Related Gene Expression Modulation
  8. [8]
    Zozulya, A. A. et al Selank anxiolytic effects Bull. Exp. Biol. Med. (2001)
  9. [7]
    Antiviral Activity Study
  10. [13]
  11. [12]
    Kozlovskaya, M. M. et al Interaction of Selank with the GABA system Bull. Exp. Biol. Med. (2003)
  12. [14]
    Medvedev et al — Anxiolytic profile of Selank in generalized anxiety disorder Zh. Nevrol. Psikhiatr. (2014)
  13. [11]
    Uchakina, O. N. et al Immunomodulatory effects of Selank Int. Immunopharmacol. (2008)
  14. [6]
Updated 2026-03-08Sources: jabronistore-wiki, peptide-wiki-mdx, pep-pedia, pubchem, peptide-wiki-mdx-v2

On this page